JP2013502913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502913A5 JP2013502913A5 JP2012526072A JP2012526072A JP2013502913A5 JP 2013502913 A5 JP2013502913 A5 JP 2013502913A5 JP 2012526072 A JP2012526072 A JP 2012526072A JP 2012526072 A JP2012526072 A JP 2012526072A JP 2013502913 A5 JP2013502913 A5 JP 2013502913A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- abm
- chain variable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23850509P | 2009-08-31 | 2009-08-31 | |
| US61/238,505 | 2009-08-31 | ||
| PCT/EP2010/062527 WO2011023787A1 (en) | 2009-08-31 | 2010-08-27 | Affinity-matured humanized anti cea monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013502913A JP2013502913A (ja) | 2013-01-31 |
| JP2013502913A5 true JP2013502913A5 (https=) | 2013-04-18 |
| JP5744872B2 JP5744872B2 (ja) | 2015-07-08 |
Family
ID=42985489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526072A Expired - Fee Related JP5744872B2 (ja) | 2009-08-31 | 2010-08-27 | 親和性成熟ヒト化抗ｃｅａモノクローナル抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9068008B2 (https=) |
| EP (1) | EP2473532B1 (https=) |
| JP (1) | JP5744872B2 (https=) |
| KR (1) | KR101528013B1 (https=) |
| CN (1) | CN102741293B (https=) |
| AR (1) | AR078111A1 (https=) |
| AU (1) | AU2010288469A1 (https=) |
| BR (1) | BR112012003983A2 (https=) |
| CA (1) | CA2770174A1 (https=) |
| CL (1) | CL2012000551A1 (https=) |
| CO (1) | CO6491105A2 (https=) |
| CR (1) | CR20120087A (https=) |
| EC (1) | ECSP12011698A (https=) |
| IL (1) | IL218038A0 (https=) |
| MA (1) | MA33536B1 (https=) |
| MX (1) | MX339608B (https=) |
| PE (1) | PE20121552A1 (https=) |
| RU (1) | RU2570554C2 (https=) |
| SG (1) | SG178567A1 (https=) |
| TW (1) | TW201121994A (https=) |
| WO (1) | WO2011023787A1 (https=) |
| ZA (1) | ZA201200954B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| PE20141017A1 (es) * | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
| NO2748201T3 (https=) | 2011-08-23 | 2018-05-12 | ||
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| GB201213858D0 (en) | 2012-08-03 | 2012-09-19 | Mab Design Ltd | Method |
| MY175687A (en) | 2012-08-07 | 2020-07-06 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
| RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| EP2961770A1 (en) * | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| US10550196B2 (en) | 2014-04-27 | 2020-02-04 | Famewave Ltd. | Humanized antibodies against CEACAM1 |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| PE20180484A1 (es) | 2015-10-02 | 2018-03-07 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| CN107663240B (zh) | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| US10882918B2 (en) | 2016-09-30 | 2021-01-05 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| TWI890481B (zh) | 2018-02-09 | 2025-07-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| CN113906053B (zh) * | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| KR20220025848A (ko) | 2019-06-26 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | Cea 및 4-1bbl에 결합하는 항체의 융합 |
| CN110713539B (zh) * | 2019-09-23 | 2021-04-16 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| CN110862456B (zh) * | 2019-09-23 | 2021-04-09 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| WO2021255155A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cd19 |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| JP2024519078A (ja) * | 2021-05-21 | 2024-05-08 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｃｅａ抗体及びその使用方法 |
| AU2023212292A1 (en) * | 2022-01-27 | 2024-09-12 | Janssen Biotech, Inc. | Enhanced protein compositions |
| KR20250024741A (ko) | 2022-03-23 | 2025-02-19 | 시나픽스 비.브이. | 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트 |
| EP4724490A2 (en) | 2023-06-12 | 2026-04-15 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| WO2025257185A1 (en) * | 2024-06-11 | 2025-12-18 | Abcely | Humanized anti-human-carcinoembryonic antigen antibody |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| AU672951B2 (en) * | 1992-05-07 | 1996-10-24 | Ge Healthcare As | Complexing agents and targeting immunoreagents |
| GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| AU8822601A (en) | 2000-07-31 | 2002-02-13 | Biolex Inc | Expression of biologically active polypeptides in duckweed |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CN1665934B (zh) | 2002-03-19 | 2010-05-26 | 国际植物研究所 | GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达 |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| JP5138867B2 (ja) * | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
| EP1539966B1 (en) | 2002-09-12 | 2010-06-30 | Greenovation Biotech GmbH | Protein production method |
| WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| US20090005257A1 (en) * | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| PE20141017A1 (es) * | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
-
2010
- 2010-08-27 KR KR1020127008265A patent/KR101528013B1/ko not_active Expired - Fee Related
- 2010-08-27 PE PE2012000266A patent/PE20121552A1/es not_active Application Discontinuation
- 2010-08-27 BR BR112012003983-0A patent/BR112012003983A2/pt not_active Application Discontinuation
- 2010-08-27 RU RU2012112340/10A patent/RU2570554C2/ru active
- 2010-08-27 EP EP10745651.9A patent/EP2473532B1/en active Active
- 2010-08-27 SG SG2012013306A patent/SG178567A1/en unknown
- 2010-08-27 CA CA2770174A patent/CA2770174A1/en not_active Abandoned
- 2010-08-27 AU AU2010288469A patent/AU2010288469A1/en not_active Abandoned
- 2010-08-27 JP JP2012526072A patent/JP5744872B2/ja not_active Expired - Fee Related
- 2010-08-27 MX MX2012002461A patent/MX339608B/es active IP Right Grant
- 2010-08-27 CN CN201080048622.1A patent/CN102741293B/zh not_active Expired - Fee Related
- 2010-08-27 WO PCT/EP2010/062527 patent/WO2011023787A1/en not_active Ceased
- 2010-08-30 AR ARP100103166A patent/AR078111A1/es not_active Application Discontinuation
- 2010-08-30 TW TW099129130A patent/TW201121994A/zh unknown
- 2010-08-31 US US12/872,908 patent/US9068008B2/en active Active
-
2012
- 2012-01-30 CO CO12014021A patent/CO6491105A2/es not_active Application Discontinuation
- 2012-02-08 ZA ZA2012/00954A patent/ZA201200954B/en unknown
- 2012-02-09 IL IL218038A patent/IL218038A0/en unknown
- 2012-02-20 CR CR20120087A patent/CR20120087A/es unknown
- 2012-02-27 MA MA34650A patent/MA33536B1/fr unknown
- 2012-02-28 EC ECSP12011698 patent/ECSP12011698A/es unknown
- 2012-02-29 CL CL2012000551A patent/CL2012000551A1/es unknown
-
2015
- 2015-05-26 US US14/721,795 patent/US20160075795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502913A5 (https=) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| TWI771361B (zh) | 人程序性死亡受體pd-1的單株抗體及其片段 | |
| CN103030695B (zh) | 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物 | |
| JP2020501531A5 (https=) | ||
| JP2014527814A5 (https=) | ||
| JP2010504755A5 (https=) | ||
| JP2023540526A5 (https=) | ||
| WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
| CN121108344A (zh) | 抗cd3抗体以及其用途 | |
| WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
| JP2025503513A (ja) | Ｃｄ３を標的にする抗体、多特異性抗体、およびその使用 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| TWI908815B (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| EP4534562A1 (en) | Bispecific antibody and application thereof | |
| WO2023222135A1 (en) | A method of treating solid tumor | |
| KR20240072932A (ko) | B7-h3에 특이적으로 결합하는 항체 | |
| JP7162011B2 (ja) | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 | |
| US20240166768A1 (en) | Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer | |
| WO2018202794A1 (en) | Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| HK40119299A (zh) | 抗cd73抗体及其用途 | |
| TW202313690A (zh) | 一種抗b7-h4抗體及其製備方法和應用 | |
| TW202521571A (zh) | 抗ｃｅａｃａｍ５抗體及其用途 |